Hap Trading, LLC Incyte Corp Put Options Transaction History

Hap Trading, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 May 12, 2022	SELL	$66.02 - $79.71 $3.83 Million - $4.62 Million	-58,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $1.28 Million - $1.5 Million	-20,200 Reduced 25.83%	58,000 $882,000
Q3 2021 Nov 10, 2021	BUY	$68.67 - $84.02 $1.85 Million - $2.26 Million	26,900 Added 52.44%	78,200 $1.24 Million
Q2 2021 Aug 11, 2021	SELL	$79.87 - $87.53 $103,831 - $113,789	-1,300 Reduced 2.47%	51,300 $593,000
Q1 2021 May 14, 2021	BUY	$76.02 - $100.5 $2.14 Million - $2.83 Million	28,200 Added 115.57%	52,600 $908,000
Q1 2019 May 10, 2019	SELL	$63.56 - $88.17 $6.38 Million - $8.84 Million	-100,300 Reduced 80.43%	24,400 $820,000
Q3 2018 Nov 09, 2018	SELL	$61.75 - $74.23 $55,575 - $66,807	-900 Reduced 0.72%	124,700 $1.32 Million
Q2 2018 Aug 13, 2018	SELL	$60.85 - $83.98 $18 Million - $24.9 Million	-296,300 Reduced 70.23%	125,600 $1.49 Million
Q1 2018 May 11, 2018	BUY	$83.06 - $100.98 $34.1 Million - $41.5 Million	411,100 Added 3806.48%	421,900 $1.81 Million
Q4 2017 Feb 09, 2018	BUY	$93.56 - $116.6 $1.01 Million - $1.26 Million	10,800	10,800 $203,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.